Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.8% – Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL) traded down 5.8% on Tuesday . The stock traded as low as $3.06 and last traded at $3.07. 126,730 shares traded hands during trading, a decline of 91% from the average session volume of 1,458,050 shares. The stock had previously closed at $3.26.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AUTL. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research report on Monday, November 11th. Finally, The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Buy” and an average price target of $10.15.

Autolus Therapeutics Price Performance

The firm has a market cap of $832.86 million, a PE ratio of -2.54 and a beta of 1.99. The stock’s fifty day moving average price is $3.72 and its 200-day moving average price is $3.91.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the firm posted ($0.26) earnings per share. On average, sell-side analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ProShare Advisors LLC bought a new position in Autolus Therapeutics in the 2nd quarter valued at $43,000. Capstone Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the third quarter worth $51,000. Daiwa Securities Group Inc. lifted its position in shares of Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares during the period. Herbst Group LLC acquired a new stake in Autolus Therapeutics during the third quarter worth approximately $91,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Autolus Therapeutics in the 1st quarter valued at about $108,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.